You are viewing the site in preview mode

Skip to main content

Advertisement

Table 5 Budget impact for PAH patients in FC II and FC III receiving beraprost and sildenafila

From: Economic evaluation of sildenafil for the treatment of pulmonary arterial hypertension in Indonesia

Year FC II FC III
beraprost sildenafil beraprost sildenafil
1 8.6 8.4 6.6 7.5
2 7.0 6.9 5.9 6.5
3 7.1 7.3 6.2 6.8
4 7.4 7.7 6.4 7.1
5 7.7 8.0 6.6 7.4
Total 37.8 38.2 31.8 35.4
  1. aAll costs presented in million USD